Novanta (NOVT) 46th Annual William Blair Growth Stock Conference summary

Strategic direction and market focus

• Shifted portfolio from 10% to over 50% exposure in medical end markets, reducing cyclicality and increasing recurring revenue streams.

• Reduced semiconductor exposure from nearly 50% to 10–15%, while increasing robotics and automation to about 20% of advanced industrial sales.

• Medical consumables now represent 15% of the portfolio, up from 0% eight years ago, growing at double digits.

• Intelligent subsystems, combining hardware and embedded software, now account for 30% of business, up from less than 5% a decade ago.

• Focused on high-growth, secular markets such as minimally invasive surgery, robotic surgery, precision medicine, and advanced industrial automation.

Innovation and technology leadership

• Provides mission-critical, proprietary technologies that are typically sole-sourced for the lifetime of customer equipment.

• Leading in end-of-arm technologies for surgical robotics, including sensing, motion control, and haptic feedback.

• Developed unique safety and sensing solutions for advanced robotics, including technology for safe robot failure and human-robot interaction.

• Supplies advanced laser and light manipulation subsystems for applications like 3D printing, EUV lithography, and GPU chip testing.

• Integrates light and motion expertise for precision medicine and life sciences, supporting high-throughput, accurate diagnostics.

Growth platforms and financial model

• Five key growth platforms: insufflation and fluid management, robotic surgery, advanced robotics, light manipulation, and precision medicine.

• About 15% of sales are linked to GenAI infrastructure, growing 20% last quarter, with further acceleration expected.

• Insufflation and fluid management business expected to double from $200M in 2024 to $400M by 2030.

• Medical consumables business now $150M, growing strong double digits, and not tied to capital investment cycles.

• M&A strategy has deployed over $1.2B across 20+ acquisitions, compounding growth and expanding technology offerings.